SMAD7 and inflammatory bowel disease: Indeed, SMAD7, which inhibits TGFβ signalling and is expressed at high levels in the intestines of patients with IBD,64 has been shown to be an effective therapeutic target via an antisense oligonucleotide (Mongersen) that binds to and degrades SMAD7 mRNA.65